Zydus receives final approval from the USFDA for Triamterene and Hydrochlorothiazide Capsules USP

Ahmedabad, 13 February, 2019

Zydus Cadila has received the final approval from the USFDA to market Triamterene and Hydrochlorothiazide Capsules USP (US RLD – DYAZIDE®), 37.5 mg/25 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The fixed dose combination of Triamterene and Hydrochlorothiazide is indicated for the treatment of hypertension or edema in patients who have developed hypokalemia (low serum potassium levels) on Hydrochlorothiazide alone. It is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked. This medication may be used alone or as an adjunct to other antihypertensive drugs.

The group now has 249 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

***